A 6-month, Phase II, Double-masked, Multicenter, Randomized, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Topical Administration of Two Concentrations of FOV2304 (High Dose or Low Dose) for the Treatment of Center-involving Clinically Significant Macular Edema Associated With Diabetic Retinopathy.

Trial Profile

A 6-month, Phase II, Double-masked, Multicenter, Randomized, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Topical Administration of Two Concentrations of FOV2304 (High Dose or Low Dose) for the Treatment of Center-involving Clinically Significant Macular Edema Associated With Diabetic Retinopathy.

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Oct 2014

At a glance

  • Drugs Safotibant (Primary)
  • Indications Diabetic macular oedema
  • Focus Therapeutic Use
  • Sponsors Fovea Pharmaceuticals
  • Most Recent Events

    • 01 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 10 Jan 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 16 Nov 2011 New source identified and integrated (European Clinical Trials Database record, EudraCT2010-021291-29).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top